Track topics on Twitter Track topics that are important to you
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Original Article: Novartis’ MabThera biosimilar wins EU nodNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...